A team from NICE have published a perspective paper on how to make use of patient preference studies in health technology assessments (HTAs) in The Patient journal.
Bouvy et al. argue that patient preferences can be insightful to committees as they determine whether or not to recommend a medicine, despite this type of evidence typically not featuring in a submission to the National Institute for Health and Care Excellence (NICE).
The authors identified three times when patient preferences could be most informative in the development and market access processes:
- selection of useful endpoints in clinical studies
- regulatory benefit-risk assessments
- HTA decision making
It is specifically noted that:
“Examples where patient preference studies might have added value in health technology assessments include cases where two distinctly different treatment options are being compared, when patients have to decide between multiple treatment options, when technologies have important non-health benefits or when a treatment is indicated for a heterogenous population.”
As NICE progresses through its methods review, it is encouraging to note their increased awareness and interest in other forms of evidence and the ways these can inform committee decision making.
Find out more here.